

## Special Issue

# Shared Mechanisms and Multimorbidity for Immune-Mediated Diseases

### Message from the Guest Editor

Immune-mediated diseases (IMDs) currently affect approximately 10% of the global population and are increasing in incidence. These diseases are typically chronic, multifactorial conditions with no cure, and they therefore pose a substantial burden for affected individuals, their families, and the healthcare system. However, understanding the biological pathways that are common to different IMDs and their co-morbid clinical phenotypes can aid the development of strategies for the improvement treatment and management of multiple conditions. This Special Issue will highlight recent advances in genetics and functional genomics that are facilitating the determination of pathophysiological mechanisms that are shared across multiple IMDs and that drive co-morbidity between IMDs and with other disorders. These advances include the development of new approaches for investigating cross-trait associations; the utilization of big data sets; and the implementation of high-throughput, high-resolution methods for patient immunoprofiling, including single-cell genomics. We welcome the submission of reviews, perspectives, short communications, and research articles.

---

### Guest Editor

Dr. Calliope Dendrou  
Wellcome Centre for Human Genetics, University of Oxford

---

### Deadline for manuscript submissions

closed (16 October 2020)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.9  
Indexed in PubMed



[mdpi.com/si/25791](https://mdpi.com/si/25791)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.9  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))